Beta Bionics, Inc.
BBNX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $65,124 | $11,995 | $179 |
| % Growth | 442.9% | 6,601.1% | – |
| Cost of Goods Sold | $29,236 | $5,687 | $0 |
| Gross Profit | $35,888 | $6,308 | $179 |
| % Margin | 55.1% | 52.6% | 100% |
| R&D Expenses | $26,184 | $17,943 | $31,428 |
| G&A Expenses | $17,869 | $12,225 | $24,668 |
| SG&A Expenses | $54,955 | $24,215 | $33,495 |
| Sales & Mktg Exp. | $37,086 | $11,990 | $8,827 |
| Other Operating Expenses | $0 | $0 | $1,100 |
| Operating Expenses | $81,139 | $42,158 | $66,023 |
| Operating Income | -$45,251 | -$35,850 | -$65,844 |
| % Margin | -69.5% | -298.9% | -36,784.4% |
| Other Income/Exp. Net | -$9,505 | -$8,249 | $1,093 |
| Pre-Tax Income | -$54,756 | -$44,099 | -$64,751 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$54,756 | -$44,099 | -$64,751 |
| % Margin | -84.1% | -367.6% | -36,173.7% |
| EPS | -8.6 | -8.31 | -12.96 |
| % Growth | -3.5% | 35.9% | – |
| EPS Diluted | -8.6 | -8.31 | -12.96 |
| Weighted Avg Shares Out | 6,365 | 5,304 | 4,998 |
| Weighted Avg Shares Out Dil | 6,365 | 5,304 | 4,998 |
| Supplemental Information | – | – | – |
| Interest Income | $3,909 | $1,777 | $196 |
| Interest Expense | $0 | $0 | $14 |
| Depreciation & Amortization | $1,151 | $1,226 | $1,345 |
| EBITDA | -$44,100 | -$34,624 | -$63,399 |
| % Margin | -67.7% | -288.7% | -35,418.4% |